Cargando…

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions

SIMPLE SUMMARY: Recurrent CTNNB1 exon 3 mutations have been recognized in the distinct group of melanocytic tumors showing deep penetrating nevus-like morphology and in 1–2% of advanced melanoma. We performed a detailed genetic analysis of difficult-to-classify nevi and melanomas with CTNNB1 mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaremba, Anne, Jansen, Philipp, Murali, Rajmohan, Mayakonda, Anand, Riedel, Anna, Krahl, Dieter, Burkhardt, Hans, John, Stefan, Géraud, Cyrill, Philip, Manuel, Kretz, Julia, Möller, Inga, Stadtler, Nadine, Sucker, Antje, Paschen, Annette, Ugurel, Selma, Zimmer, Lisa, Livingstone, Elisabeth, Horn, Susanne, Plass, Christoph, Schadendorf, Dirk, Hadaschik, Eva, Lutsik, Pavlo, Griewank, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454999/ https://www.ncbi.nlm.nih.gov/pubmed/36077603 http://dx.doi.org/10.3390/cancers14174066

Ejemplares similares

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
por: Thielmann, Carl Maximilian, et al.
Publicado: (2022)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
por: Jansen, Philipp, et al.
Publicado: (2021)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Griewank, Klaus G., et al.
Publicado: (2013)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
por: Stiller, Mathias, et al.
Publicado: (2016)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
por: Sucker, Antje, et al.
Publicado: (2017)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition
por: Hegedüs, Luca, et al.
Publicado: (2022)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Association of Differentially Altered Liver Fibrosis with Deposition of TGFBi in Stabilin-Deficient Mice
por: Krzistetzko, Jessica, et al.
Publicado: (2023)

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
por: Smith, Charlotte, et al.
Publicado: (2023)

CTNNB1 in neurodevelopmental disorders
por: Zhuang, Wenting, et al.
Publicado: (2023)

Germline mutations in BAP1 predispose to melanocytic tumors
por: Wiesner, Thomas, et al.
Publicado: (2011)

Slowly Growing Annular Erythematous Lesions on Lightly Pigmented Skin: A Quiz
por: OLSAVSZKY, Victor, et al.
Publicado: (2020)

The Role of CTNNB1 in Endometrial Cancer
por: Ledinek, Živa, et al.
Publicado: (2022)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

CTNNB1 Mutation in Aldosterone Producing Adenoma
por: Wang, Jian-Jhong, et al.
Publicado: (2017)

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma
por: Apps, J. R., et al.
Publicado: (2020)

Recurrent CTNNB1 mutations in craniofacial osteomas
por: Baumhoer, Daniel, et al.
Publicado: (2021)

Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide Images
por: Jansen, Philipp, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n1c8djue1bgma1qmgr3j4oklpr